- $1.91bn
- $1.65bn
- $1.09bn
- 96
- 50
- 16
- 53
Annual income statement for Progyny, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 230 | 345 | 501 | 787 | 1,089 |
Cost of Revenue | |||||
Gross Profit | 45.5 | 70.1 | 112 | 167 | 239 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 220 | 337 | 468 | 764 | 1,026 |
Operating Profit | 9.68 | 8.35 | 32.3 | 23.3 | 62.2 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.56 | 8.68 | 32.4 | 24.4 | 70.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.57 | 46.5 | 65.8 | 30.4 | 62 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -8.57 | 46.5 | 65.8 | 30.4 | 62 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.57 | 46.5 | 65.8 | 30.4 | 62 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.074 | 0.536 | 0.655 | 0.304 | 0.616 |